JPI-283

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameJPI-283
Drug Alias NameJPI-283
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsTankyrase-1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors +[4] 
TargetsTankyrase-1Poly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJeil Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJeil Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A